• View Press Releases

    View Press Releases

News & Media

Recent News

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma More

Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb More

Seattle Genetics Reports Second Quarter 2017 Financial Results More

View All News

Quick Facts

Year founded 1998

Nasdaq SGEN

Number of Employees 1,000+

Global Headquarters Bothell, WA

European Headquarters Zug, Switzerland

icon-sw.png

Primary Product ADCETRIS

adcetris.png

Disease Focus Areas Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, breast cancer, acute myeloid leukemia

heart.png

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+

Resources

Social Media

 

Media Contacts

For Media Professionals Only

Brandi Robinson

Sr. VP, Corporate Communications

media@seagen.com